In national prospective study, 2.9% of those undergoing anesthesia reported receiving GLP-1 receptor agonists.

Phase 3 PROPEL 3 trial results show daily oral infigratinib significantly improved annualized height velocity and height Z-scores compared with placebo in children with achondroplasia.

Phase 3b trial shows long-acting injectable therapy outperforms daily oral regimens for patients with detectable HIV-1 and adherence challenges.

Combined tobacco and e-cigarette exposure linked to increase in activity-related symptoms, nighttime symptoms, albuterol use.

Net decreases in prevalence seen across age groups, with largest relative reduction for young adults aged 18 to 29 years.